TABLE 1.

Study population

	Patients with cirrhosis (n = 16)																Patients without cirrhosis (n = 7)
	P2	P4	P6	P7	P9	P10	P11	P12	P13	P14	P17	P18	P19	P20	P21	P23	P1	P3	P5	P8	P15	P16	P22
Sex/Age	M/68	F/46	F/67	M/52	M/51	F/37	M/42	F/45	M/66	F68	F36	M/59	M/37	F/50	F/64	M/53	F/66	F/42	M/42	F/29	F36	F39	M/30
Previous IFN	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
HDV‐RNA copies/mL	2.8e6	2.1e6	1.6e5	7.1e2	3.7e3	2.7e5	3.1e4	1.2e4	5.8e3	8.2e5	1.0e2	1.0e6	1.6e6	4.3e5	2.1e7	2.1e7	5.9e6	5.2e5	9.5e4	4.3e5	1.1e6	2.3e3	2.1e7
HBeAg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	pos	neg	pos	neg	neg	neg
HBV‐DNA (IU/mL)	<20	neg	<20	neg	neg	63	<20	neg	neg	neg	neg	neg	neg	347	neg	0	21	<20	neg	<20	neg	<20	6000
HBsAg, quant	3142	9377	420	1229	1663	—	13,649	181	45	2090	2266	4673	2183	1161	—	—	9780	11,825	1090	17,326	5890	3643	—
VCTE‐LSM (kPa)	26.3	17.2	10.2	—	35.8	14.6	22.7	18.6	7.5	—	24	—	48	19.4	—	31.6	—	9.1	7.4	5.5	7	9.5	6.8
Bilirubin (mg/dl)	1.38	0.52	0.35	0.49	0.95	1.2	1.37	1.12	1.35	1.54	0.65	1.24	0.8	1.6	0.3	1.6	0.36	0.47	0.52	0.5	0.28	0.65	0.64
Albumin (g/dl)	34.4	31.0	44.8	44.1	46.1	43.0	38.1	41.8	39.9	33.9	49.9	41.9	36.7	32.5	41.0	34.9	41.3	45.6	44.0	35.6	43.0	45.6	47.6
INR	1.3	1.4	1.0	1.0	1.2	1.2	1.2	1.0	1.4	1.7	1.2	1.2	2.4	1.3	1.0	1.4	1.0	1.0	1.0	1.2	1.1	1.3	1.0
Platelets (G/L)	77	98	131	166	84	129	109	29	90	63	85	86	78	53	126	140	216	251	162	288	257	206	166
AST (IU/L)	55	93	64	21	68	48	87	35	36	94	24	101	56	315	50	120	111	76	68	53	51	203	43
ALT (IU/L)	63	80	75	25	125	56	115	35	44	69	24	132	73	307	42	100	224	91	207	42	59	341	98
GGT (IU/L)	30	52	43	37	98	31	177	16	26	48	30	88	141	82	45	91	44	64	86	16	32	58	49
Concomitant NAtherapy	ETV	ETV	TDF	TDF	ETV	TAF	TDF	No	TDF	TAF	TDF	TDF	TDF	TDF	TDF	TDF	TDF	TDF	TDF	No	TDF	TDF	TDF

Abbreviations: ETV, entecavir; NUC, nucleos(t)ide analog; TAF, tenofovir alafenamide; TDF, tenofovir disoprixile fumarate; VCTE‐LSM, liver stiffness measurement by vibration controlled transient elastography.